Adalimumab in refractory paediatric ulcerative colitis

被引：0
|
作者：
Volonaki, E. [1 ]
Kiparissi, F. [1 ]
Shah, N. [1 ]
Lindley, K. J. [1 ]
Elawad, M. [1 ]
机构：
[1] Great Ormond St Hosp Sick Children, London WC1N 3JH, England
来源：
JOURNAL OF CROHNS & COLITIS | 2014年 / 8卷
关键词：
D O I：
10.1016/S1873-9946(14)50144-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P-116
引用
收藏
页码：S435 / S436
页数：2
相关论文
共 50 条
  • [1] Envisioning adalimumab for paediatric patients with ulcerative colitis
    Ray K.
    Nature Reviews Gastroenterology & Hepatology, 2021, 18 (9) : 594 - 594
  • [2] Efficacy of Adalimumab in Refractory Ulcerative Colitis in Clinical Practice
    Lequoy, Marie
    Seksik, Philippe
    Bouhnik, Yoram
    Allez, Matthieu
    Carbonnel, Franck
    Bourrier, Anne
    Sokol, Harry
    Beaugerie, Laurent
    Cosnes, Jacques
    GASTROENTEROLOGY, 2013, 144 (05) : S203 - S203
  • [3] Evaluation of adalimumab effectiveness in paediatric patients with ulcerative colitis in clinical practice
    Steiner, S.
    Liu, C.
    King, E.
    Israel, E.
    Pasternak, B.
    Schaefer, M.
    Chen, S.
    Pratt, J.
    Lazar, A.
    Bereswill, M.
    Robinson, A.
    Colletti, R.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S369 - S370
  • [4] Successful use of golimumab in a patient with ulcerative colitis refractory to infliximab and adalimumab
    Cortes, Xavier
    Borras-Blasco, Joaquin
    Flor, Laura
    Antequera, Beatriz
    Fernandez-Martinez, Sergio
    Ramon Moles, Jose
    Castera, Elvira
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2021, 59 (03) : 257 - 260
  • [5] Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
    Xie F.
    Blackhouse G.
    Assasi N.
    Gaebel K.
    Robertson D.
    Goeree R.
    Cost Effectiveness and Resource Allocation, 7 (1)
  • [6] Oral tacrolimus (FK 506) in refractory paediatric ulcerative colitis
    Romano, C.
    Comito, D.
    Famiani, A.
    Fries, W.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (06) : 676 - 677
  • [7] Adalimumab in patients with ulcerative colitis
    Balatsos, V.
    Anastasiou, Th.
    Karoumpalis, I.
    Katselis, I.
    Vagia, A.
    Skandalis, N.
    ANNALS OF GASTROENTEROLOGY, 2010, 23 (01): : 64 - 66
  • [8] The economics of adalimumab for ulcerative colitis
    Xie, Feng
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (03) : 373 - 377
  • [9] Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis
    Volonaki, Eleni
    Mutalib, Mohamed
    Kiparissi, Fevronia
    Shah, Neil
    Lindley, Keith J.
    Elawad, Mamoun
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 27 (12) : 1425 - 1428
  • [10] Long term assessment of clinical response to Adalimumab therapy in refractory Ulcerative Colitis
    Hussey, M.
    Mc Garrigle, R.
    Kennedy, U.
    Holleran, G.
    Kevans, D.
    Breslin, N.
    Ryan, B.
    Mahmud, N.
    McNamara, D.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2015, 184 : S216 - S217
12345